A descriptive study of BRCA1 testing and reactions to disclosure of test results
Open Access
- 1 June 1997
- Vol. 79 (11) , 2219-2228
- https://doi.org/10.1002/(sici)1097-0142(19970601)79:11<2219::aid-cncr21>3.0.co;2-y
Abstract
BACKGROUND The identification of the BRCA1 gene is a powerful tool for predicting a patient's lifetime risk for carcinoma of the breast and ovary when she has hereditary breast/ovarian carcinoma (HBOC) syndrome. The process of BRCA1 testing and genetic counseling, and participants' reactions to test results, are described. METHODS Education about the natural history of HBOC syndrome and the pros and cons of genetic testing was provided to 14 HBOC families comprised of 2549 bloodline relatives. Of these, 388 underwent DNA testing. After informed consent was given by participants, formal linkage analysis and gene mutation studies were performed on the families. Qualitative data on intentions and emotional reactions were collected by physicians/counselors during the genetic counseling sessions. RESULTS Of those tested, 181 received their results after further genetic counseling. Seventy‐eight of them were positive and 100 were negative for BRCA1 gene mutation. Three had ambiguous findings. The most common reasons given for seeking DNA testing were concern about risk to children and concern about surveillance and prevention. Prophylactic mastectomy was considered by 35% of women who tested positive, whereas prophylactic oophorectomy was considered an important option by 76%. Twenty‐five percent of both BRCA1 positive and negative individuals were concerned about discrimination by insurance companies. Eighty percent of those who tested negative reported emotional relief, whereas over one‐third of those who tested positive reported sadness, anger, or guilt. CONCLUSIONS DNA testing of patients with HBOC syndrome must be performed in the context of genetic counseling. The authors' results demonstrate the many complex clinical and nonclinical issues that are important in this process. [See editorial counterpoint on pages 2063‐5 and reply to counterpoint on pages , this issue.] Cancer 1997; 79:2219‐28. © 1997 American Cancer Society.Keywords
This publication has 12 references indexed in Scilit:
- BRCA1 Testing in Families With Hereditary Breast-Ovarian CancerJAMA, 1996
- Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkageCancer, 1996
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995
- A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1Science, 1994
- The genetic testing of children. Working Party of the Clinical Genetics Society (UK)Journal of Medical Genetics, 1994
- Risks of cancer in BRCA1-mutation carriersThe Lancet, 1994
- Summary of Report: “Heredity: Science and Society. On the Possibilities and Limits of Genetic Testing and Gene Therapy.” Report issued by a Committee of the Health Council of The Netherlands, December 29, 1989Human Gene Therapy, 1994
- DNA Screening for Breast/Ovarian Cancer Susceptibility Based on Linked MarkersArchives of internal medicine (1960), 1993
- Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21Science, 1990